Tagged with antibiotics

Global Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from the pharma companies that manufacture lifesaving antibiotics and antifungals to ensure that patients can get the right medicine when they…

Europe The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his perspective on recent policy changes at a national and continental level. With over ten years of experience with the company,…

Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it.   Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…

Saudi Arabia Medochemie’s Yasser Sabra gives a fascinating insight into the branded generic and value added medicine field today, including why the COVID-19 pandemic could lead to a reappraisal of medicine repurposing. Sabra also touches on the firm’s operations in the Middle East’s biggest market of Saudi Arabia, explaining why the Saudi…

Sweden Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been a pioneer in the field, and Blanck believes that Sweden is an excellent test market for various incentive models that,…

Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm.   AI has the power to enable biopharmaceutical companies to reduce costs and improve…

Opinion Steve Brooks, Advisor to the AMR Industry Alliance, outlines the threat that antimicrobial resistance (AMR) poses to global health,  how antibiotic manufacturing may be a contributing factor to AMR  and how responsible manufacturing processes can minimize any such contribution.   The causes of antimicrobial resistance are numerous, from over prescribing to…

Novartis In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral early-stage research programs, laying off 140 staff in the US. This comes at a time when antibiotic-resistant strains of bacteria – so-called ‘superbugs’ – are…

Switzerland Giacomo Di Nepi, CEO of innovative Swiss specialty pharma outfit Polyphor, discusses his decision to join the company in 2016, his main priorities, and the potential impact of an IPO in the next two years. Having previously held senior leadership responsibilities with Takeda and Novartis, spending time as partner at…

Mexico Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s region-wide commitment to offering reliable, compliant and sustainable APIs. Could you please introduce to our international audience the key activities…

cardiology The general manager of Argentia weighs up the factors that have led to his company consolidating its different business lines and becoming one of the fastest growing companies in Argentina.   What was your main objective upon joining Argentia? In 1995, Argentia was acquired by BMS and was sold to…